The only RCT of viability testing was PARR-2, which used PET. There was no benefit from viability testing for cardiac events but there were many limitations including failure of randomized management (25% with viability did not have revascularization). ht
4,937 followers
117 followers
@phillipfreeman I see the PARR 2 trial cited a lot for pet. No significant difference in mace but when in patients who adhered to pet recommendation for intervention, there was a significant improvement. But could be bias. https://t.co/xpAUxk5gPu
10,391 followers
Sin embargo la evidencia fue paulatinamente cambiando y el PET, por mucho tiempo estándar de oro, no pudo demostrar beneficio en el estudio PARR-2. https://t.co/nvsdYV2ZBx
20,062 followers
ViabilityはPET単独というより、合わせ技が多いかと PARR-2 trial https://t.co/6HRHJTLwZd 今進行中の研究 https://t.co/LKBMkOfuuw By 情報広報委員M